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Abstract
Background: Many patients with chronic heart failure (CHF), a common condition with high morbidity and
mortality rates, receive treatment in primary care. To improve the management of CHF in primary care, we
developed an implementation programme comprised of educational and organisational components, with support
by a practice visitor and focus both on drug treatment and lifestyle advice, and on organisation of care within the
practice and collaboration with other healthcare providers. Tailoring has been shown to improve the success of
implementation programmes, but little is known about what would be best methods for tailoring, specifically with
respect to CHF in primary care.
Methods/design: We describe the study protocol of a cluster randomised controlled trial to examine the
effectiveness of tailoring a CHF implementation programme to general practices compared to a standardised way
of delivering a programme. The study population will consist of 60 general practitioners (GPs) and the CHF
patients they include. GPs are randomised in blocks of four, stratified according to practice size. With a tailored
implementation programme GPs prioritise the issues that will form the bases of the support for the practice visits.
These may comprise several issues, both educational and organizational.
The primary outcome measures are patient’s experience of receiving structured primary care for CHF (PACIC, a
questionnaire related to the Chronic Care Model), patients’ health-related utilities (EQ-5D), and drugs prescriptions
using the guideline adherence index. Patients being clustered in practices, multilevel regression analyses will be
used to explore the effect of practice size and type of intervention programme. In addition we will examine both
changes within groups and differences at follow-up between groups with respect to drug dosages and advice on
lifestyle issues. Furthermore, in interviews the feasibility of the programme and goal attainment, organisational
changes in CHF care, and formalised cooperation with other disciplines will be assessed.
Discussion: In the tailoring of the programme we will present the GPs a list with barriers; GPs will assess relevance
and possibility to solve these barriers. The list is rigorously developed and tested in various projects. The factors for
ordering the barriers are related to the innovation, the healthcare professional, the patient, and the context.
CHF patients do not form a homogeneous group. Subgroup analyses will be performed based on the distinction
between systolic CHF and CHF with preserved left ventricular function (diastolic CHF).
Trial registration: ISRCTN: ISRCTN18812755
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Chronic heart failure (CHF) is a highly prevalent chronic
disease with high morbidity and mortality rates. The
prevalence of CHF in the Western world is 1% to 2% in
the general population and at least 10% among the age
group of 85 years and older [1,2]. Mortality in CHF
patients is high compared to their age group [2,3]. High
morbidity is associated with high hospital admission
rates and reduced quality of life [4]. There are effective,
evidence-based treatments which improve mortality and
morbidity but use of and adherence of treatments is
suboptimal despite clinical guidelines [5-9].
A large group of patients with CHF receive treatment
in primary care. There are many programmes for the
management of long-term conditions in primary care –
e.g., diabetes, COPD and depression – b u ta tp r e s e n t
not for CHF, though several disease management pro-
grammes exist for CHF related to outpatient clinics. As
a substantial proportion of CHF patients do not attend
such clinics but visit their GP instead, these patients are
not enrolled in a structured care programme.
To improve the management of CHF in primary care,
we have developed an implementation programme,
comprising both educational and organisational compo-
nents, the latter aimed at improved and structured care.
We pilot tested this programme in 19 general practices
[10]. The pilot programme was targeted at implement-
ing the prevailing practice guideline for general practice
[11]. In the mean time, in the Netherlands an interdisci-
plinary guideline on CHF, based on the European
Society of Cardiology (ESC) guideline, was developed
and published in May 2010 [12]. So, we adapted the
implementation programme according to this new
guideline, taking into account the lessons learned in the
pilot study.
A p a r tf r o mo f f e r i n gas t a n d ard implementation pro-
gramme, another approach is to tailor an intervention to
the special needs and conditions in a general practice. Ide-
ally, tailoring has three components: identification of fac-
tors associated with implementation (or labelled as
‘barriers to change’), to match implementation interven-
tions to those factors, and evaluation of the tailored imple-
mentation programme. Tailoring has been shown to have
a modest effect on the success of the implementation pro-
gramme [13], but little is known about what would be best
methods for tailoring [14]. In addition, research evidence
specifically supporting this hypothesis with respect to
improving primary care for CHF patients is not yet avail-
able. In one study no relation was found between barriers
perceived and ACE inhibitor prescription behaviour [15].
Earlier studies to improve CHF patients care focused on
disease management programmes, mainly case manage-
ment, and on education and drug prescription [16,17].
Patients being clustered in practices, we planned to
conduct a cluster randomised controlled trial with ran-
domisation at the practice level. The aim of the study
will be to examine the effectiveness of tailoring the
implementation programme to general practices com-
pared to a standardised way of delivering the implemen-
tation programme to general practices.
Methods
The project will be a collaborative project of IQ health-
care, a research department of Radboud University Nij-
megen Medical Centre, and the four regional supportive
structures for primary care (’ROS’) in the south of the
Netherlands and their cooperative bond Robuust. The
medical ethical committee (CMO Regio Arnhem –
Nijmegen) assessed the study proposal and waived
approval.
Participants
The study population will consist of 60 general practi-
tioners (GPs) and the CHF patients they will include.
GPs will be recruited in the south of the Netherlands,
contacted either directly or indirectly via various regio-
nal organisations by advisors of the regional supportive
structures for primary care. GPs will be informed about
the project, and when they agree to participate they will
be instructed to send in an admission form with data on
practice organization necessary for stratification and
randomization.
Evidence of change will be assessed by studying the
effects of the intervention on patients with CHF regis-
tered with the participating GPs. As in the pilot [10],
GPs will include all CHF patients from their practices
who are over 18 years of age of whom the GPs consider
themselves to be the physician taking care of the treat-
ment of this condition in the patient. We expect eight
to ten patients per practice [18,19]. Patients will be sent
explanation about the study and asked for informed
consent to participate in a patient questionnaire. Data
collection will be anonymized.
Interventions
Standardised delivery of the implementation programme
The implementation pack contains educational materials
for the professionals and patients. There is a recom-
mended protocol for multidisciplinary management and
a template for clinical care presented as a guiding regis-
tration form. Furthermore, we offer support by a visiting
practice consultant and the possibility to contact a GP
with a special interest in CHF management.
The project materials from the pilot were amended fol-
l o w i n gt h ep i l o ts t u d ya n dt h ed e v e l o p m e n to ft h en e w
interdisciplinary practice guideline [12]. Participating GPs
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primary care disciplines, e.g., dieticians and physiothera-
pists, and these professionals will be informed about the
project, encouraging the role of the multidisciplinary team
in CHF management. The paragraph on non-pharmaceu-
tical treatment was enlarged and the pharmaceutical para-
graph had some changes. Now, recommendations on drug
treatment are different for patients with systolic CHF
compared to patients with a preserved systolic heart func-
tion, so called diastolic CHF (See Table 1). Finally, new
recommendations on the use of devices were formulated.
The paper template is used to direct care and collect
data to demonstrate the effectiveness of the interven-
tions. Demographic data is collected in particular the
aetiology of the CHF and the diagnostic category,
whether diagnosis was echocardiography based, on the
existence of diastolic or systolic CHF, and pharmaceuti-
cal treatment at the start of the project period. A second
page poses questions about non-pharmaceutical issues
such as advice about physical activity and influenza vac-
cination. Finally, we offer different forms for patients
with systolic or diastolic CHF, based on the recommen-
dations on medication as summarised in Table 1.
The pilot study demonstrated that three practice visits
was the optimum number and these shall be offered to
all participating practices. The practice visitor is an edu-
cational facilitator trained in supporting behaviour
change in practices.
The pilot study also demonstrated that there was little
multidisciplinary clinical activity in the improvement of
care for CHF patients, and this has been addressed in this
project. We now use the multidisciplinary practice guide-
line as a starting point instead of the monodisciplinary
GP’s practice guideline. Furthermore, the regional advisors
will determine the social network in the practice area, pro-
viding information on other primary care disciplines, e.g.,
dieticians and physiotherapists, with extra expertise and
interest in CHF treatment. These workers in the other dis-
ciplines will be informed about the project and receive
relevant information in line with the multidisciplinary
guideline.
All materials are offered paper based in a binder. We
will also present all materials on a website and examine
the possibilities for designing the guiding patient regis-
tration forms on this website as well.
Tailored delivery of the implementation intervention
The intervention group of practices will have the agenda
of their practice visits determined by the results of a
questionnaire identifying the barriers they perceive to
the introduction of a programme for the management
of CHF in primary care. The barriers listed in the ques-
tionnaire are based on previous research and grouped in
relation to the innovation, the healthcare professional,
the patient, and the context [20]. GPs are asked to indi-
cate the relevance of each barrier in their practice situa-
tion on a five-point scale, and whether or not they think
t h a tt h eb a r r i e rc a nb es o l v e d .T a b l e2s h o w ss o m e
examples of barriers suggested in the format of the
questionnaire. GPs are offered the possibility to add bar-
riers they perceive that are not yet identified. When bar-
riers are identified, those that are relevant and solvable
will be prioritised and addressed during the practice
visits.
Objectives
The objective of the study is to examine the effective-
ness of identifying barriers to change, and tailoring edu-
cation and support in comparison with a standard
intervention programme, to improve the management of
patients with CHFin primary care.
Our null hypothesis is that tailoring does not result in
better implementation of the guidelines for CHF com-
pared to a standardised delivery of our implementation
programme. In addition, we will also examine whether
either of the two programmes are associated with
improvements in healthcare delivery and patient
outcomes.
Measures
Data collection will comprise the following measures:
patient questionnaires, patient registration forms, and
telephone interviews with the GPs. Practices will send
out patient questionnaires based on validated and pre-
vious used questionnaires: PACIC [21], EQ-5D [22],
questions about ‘continuity of care,’ and Morisky’s ques-
tionnaire on medication adherence [23]. In the patient
Table 1 Changes in medication advice
Medication advice based on
the 2005 GP practice guideline
Medication advice based on the
2010 multidisciplinary guideline
One scheme: Systolic heart failure:
- Diuretics - ACE inhibitor (or ARB if not
tolerated) in evidence based
doses
- ACE inhibitors or ARB - Diuretics for fluid retention
- Beta blocker - Beta blocker blockers licensed
for heart failure in evidence
based doses
- Aldosteron antagonist - Aldosterone antagonist or ARB
- Digoxin - Digoxin or H + ISND
Diastolic heart failure:
- Diuretic if signs of fluid
retention
- Adequate treatment of co
morbidity
- Strict blood pressure control
ARB = angiotensin II receptor blocker.
H + ISDN = Hydralazine + isosorbide dinitrate.
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drug therapy are registered by the GPs and their staff:
they register the baseline treatment at inclusion, and
during the patient contacts throughout the study period
they register all advice given, referrals, drug therapy
changes, and information on hospitalisation and mortal-
ity. The GP interview will score goal attainment and a
qualitative assessment of the programme. All measures
have been applied by our group in previous studies.
Outcomes
The primary outcome measures are determined at the
patients’ level and consist of experience of receiving
structured primary care for CHF (PACIC) and health-
related utilities (EQ-5D), and of drug prescriptions.
PACIC is a questionnaire consisting of 27 items,
which is related to the Chronic Care Model [24]. We
translated and validated PACIC for use in general prac-
tice in the Netherlands [25]. EQ-5D consists of five
questions and a Visual Analogue Scale (VAS), which has
been validated for use in the Netherlands [26]. These
outcome measures reflect key aspects of medical treat-
ment, organization of care, and patient reported quality
of life, and were chosen pragmatically because of the
availability of relevant, validated, responsive, composite
measures.
Drug prescription scores are assessed using the guide-
line adherence index (GAI), indicating the proportion of
indicated drugs that is prescribed [27,28]. These include
ACE inhibitors and beta blockers, and – depending on
the patient’s CHF severity according to the NYHA
classes – further drug classes [12].
Secondary outcome measures at the patients’ level
concern lifestyle advice and medication during the study
period, based on the patient registration forms providing
information on non-pharmaceutical advice and drug
prescriptions, continuity of care, and medication adher-
ence. Considering drug therapy we will assess the per-
centages of ACE inhibitors and beta blockers prescribed
in the evidence-based target dosages. Secondary out-
come measures at the practice level are goal attainment
and qualitative assessment of the programme, focussing
o nt h es u b j e c t i v eG P ’s experiences, for instance on
improvement of practice organisation and collaboration
with other primary care professionals.
Randomisation
The study will be a randomised controlled trial, with a
one-year follow-up period. Practices are stratified
according to practice size as solo, duo, or group prac-
tice. On inclusion, practices are assigned to one of the
study groups using randomisation in blocks of four per
stratum by a research assistant. Blocks were generated
electronically with the help of a statistician. The rando-
mising procedure itself is concealed for practices, con-
sultants, and researchers (JvL, MW). The regional
Table 2 Examples of possible barriers as presented in the GP’s questionnaire for the tailored intervention
To what extend is this barrier
relevant for your practice
situation?
Do you consider it possible to
solve this barrier in your practice
situation?
1. Innovation
The recommendations in the multidisciplinary practice guideline
heart failure ask for changes in our existing practice routines that are
too big.
❑ Not at all
❑ A little
❑ Neutral
❑ Relevant
❑ Very relevant
❑ Yes
❑ No
❑ Doubtful
2. Health care professional
I lack sufficient knowledge of the recommendations in the
multidisciplinary practice guideline heart failure.
❑ Not at all
❑ A little
❑ Neutral
❑ Relevant
❑ Very relevant
❑ Yes
❑ No
❑ Doubtful
3. Patient
Considering patients with complex health issues all time reserved
usually is taken completely by the actual problems and we do not
manage to provide a more structured approach for the heart failure
problems.
❑ Not at all
❑ A little
❑ Neutral
❑ Relevant
❑ Very relevant
❑ Yes
❑ No
❑ Doubtful
4. Context
We lack sufficient supportive staff to provide care according to the
practice guideline.
❑ Not at all
❑ A little
❑ Neutral
❑ Relevant
❑ Very relevant
❑ Yes
❑ No
❑ Doubtful
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randomisation process. After randomisation, both
the practice and the regional advisor are informed. The
intervention is open to all involved.
Data analysis
The primary analysis is a comparison of primary out-
comes at follow-up between the study groups, taking
into account clustering of patients within practices.
Multilevel regression analyses will be used to explore
t h ee f f e c to fp r a c t i c es i z ea nd type of intervention pro-
g r a m m e .I na d d i t i o n ,w ew i l l examine both changes
within groups and differences at follow-up between
groups with respect to percentage of patients on the
maximum tolerated dosage of ACE inhibitor or angio-
tensin II receptor blocker and of beta blockage; medica-
tion completely according to the guideline; having
received influenza vaccination in the winter season
2010-2011; having received professionally guided
physical activity training; and the number of non-
pharmaceutical issues addressed. If possible, subgroup
analyses will comprise type of CHF (systolic or diastolic)
and diagnostic certainty (secondary care diagnosis,
echocardiography diagnosis) The interviews will be used
to assess the feasibility of the programme and goal
attainment, organisational changes in CHF care, and
formalised cooperation with other primary care dis-
ciplines and specialist care.
Sample size
Power calculations are based on the primary outcome
measurement PACIC. The PACIC comprises 27 ques-
tions with an answering scale from 1 to 5. A previous
unreported study showed that its standard deviation was
1.0. To detect a difference of 0.3 points with a standard
deviation of 1 (a relatively small effect), with alpha =
0.05 and beta = 0.20, ICC = 0.05, a total of 51 practices
with 10 patients each would be required, or 59 practices
with 8 patients.
Time frame
Practice inclusion is planned from June until October
2010. After inclusion, practices participate in the pro-
gramme during one year. At the start of the year, the
GPs include all their patients with CHF they treat at
least in part themselves. During that year, patients with
newly diagnosed CHF can also be included. Data man-
agement in the patient registration forms is a continu-
ous process during the project year. After the project
period of a year, the forms are anonymised and sent to
the researchers coded. Furthermore, practices will send
coded patient questionnaires with explanation of the
survey and ask for an informed consent; these will be
returned to the researchers. Finally the researchers will
contact the GPs participating for the telephone inter-
view. The GPs will receive feedback based on the patient
registration forms and the questionnaires.
Discussion
There exist various classifications of barriers (and facilita-
tors) and multiple approaches for linking interventions to
barriers [29-31]. In their systematic review, Légaré and
colleagues propose a conceptual framework with knowl-
edge, attitude, and behaviour as main factors [31]. Our
choice of barriers is based on a list rigorously developed
in the Netherlands with a literature study in 2002, expert
input, and tested in various projects in the Netherlands
[20]. Our main factors for ordering the barriers are
related to the innovation, the healthcare professional, the
patient, and the context. The barriers presented in this
study correspond very well to the barriers found most
often in the Légaré review, including time pressure and
lack of applicability. Looking for the barriers for each
individual practice and not for the practices participating
in general, we decided to have the barriers proposed
scored in email contact with the GPs in two rounds.
Several studies were conducted to assess the effect of
tailoring implementation. In a systematic review, the
authors conclude that identifying barriers and tailoring
intervention to these barriers may improve clinical prac-
tice compared to no intervention and to guideline disse-
mination. In their meta analysis including eight studies
identified with a non-tailored intervention in the control
group, they report a modest effect of tailoring [13].
All data collection will take place at the end of the
project period. Within the context of the evaluation of
the implementation project, it is not feasible to have
data collection both at the start and at the end, but the
patient registration form will have baseline data on
treatment issues. This also will allow for within group
analyses, giving information about the effectiveness of
both implementation strategies separately. Unfortu-
nately, this data collection, either paper based or electro-
nically, will require additional administrative actions
from the practices. Enabling data collection from the
electronic medical record will be beyond the scope of
this project. Considering the patient questionnaire’s
results, with one measurement at the end, this restricts
us to intergroup analyses.
Our sample size is based on power calculation consid-
ering the PACIC outcomes. In previous research, a dif-
ference of 0.5 was found in the evaluation of a CHF and
a diabetes programme [32,33]. Thus, an effect size of 0.3
on PACIC can be considered a modest effect. We aim
at a lowered effect because we compare two strategies
that are both to be expected to have some impact.
Drug prescription is also a primary outcome measure.
We will present the GAI as a measure for the percentage
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patients appeared to receive suboptimal dosages. When
considering ACE inhibitors and beta blockers, we will
report on the percentage of prescriptions in the indi-
cated, high-target dosages [34].
We decided to stratify practices included based on
practice size. There is some evidence of a relation
between practice size and quality of care [35,37]. In one
study, larger practice size was associated with more
structured care [35]. Stratification of practices based on
practice size could be defined as the number of GPs in
the practice and based on patient list size. We choose a
stratification scheme based on the former, with the
strata solo, duo, and group practices, which appeared
feasible in previous research leading to strata of compar-
able size.
CHF patients do not form a homogeneous group;
apart from aetiology, we make a distinction between sys-
tolic CHF and CHF with preserved left ventricular func-
tion (diastolic CHF). In our study, both patient groups
m a yb ei n c l u d e d ,a st h ep r a c t i c eg u i d e l i n eg i v e sr e c o m -
mendations for both the patients with and without left
ventricular systolic dysfunction. Subgroup analyses will
be performed.
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